Hemophilia Treatment Market Size, Industry Analysis Report, Regional Outlook (U.S., Canada, Germany, UK, France, Spain, Italy, Japan, India, China, Australia, Brazil, Mexico, Saudi Arabia, South Africa), Application Development Potential, Price Trends, Competitive Market Share & Forecast, 2018 – 2024
Report ID: GMI2772
Hemophilia Treatment Market size is projected to experience significant growth from 2018 to 2024.
Increasing prevalence of hemophilia worldwide will drive the hemophilia treatment market in foreseeable future. According to National Hemophilia Foundation, the worldwide incidence of hemophilia is around 400,000 and occurs in approximately 1 in 5000 live male births. Rise in number of people suffering from hemophilia and increasing cases of genetic abnormalities will result in propelling the business growth.
Increase in demand for hemophilia treatment to fulfill the unmet needs of people across the globe is one of the major market growth driving factors. According to National Hemophilia Foundation, over 75% people with hemophilia in the world still receive inadequate or no treatment. The wide range of scope for market penetration and demand for hemophilia treatment will significantly impact the industry growth in future.
Improving healthcare infrastructure in the developing regions of Asia Pacific and Latin America region will augment the hemophilia treatment market. Increasing investment in R&D activities, increasing government initiatives and healthcare infrastructure will assist in industry size expansion. Rise in the number and improved infrastructure of public and private healthcare facilities will foster growth opportunities for hemophilia treatment market.
Lack of awareness among the patients regarding hemophilia and the treatment associated with it will be a market impeding factor. A majority of the hemophilic patients live in the developing countries, that has little or no access to hemophilia treatment, leading to increasing number of morbidity and mortality. Lack of awareness among people, low level of recognition and diagnosis of hemophilic patients, and lack of skilled healthcare professionals will impede the business growth.
Increasing use of desmopressin to prevent excessive bleeding will further boost the growth of hemophilia treatment market in the coming years. Desmopressin can be used to infuse the release of von Willebrand factor to control the bleeding and promote proper blood coagulation. According to recent research study it was found that desmopressin is quite effective in treating hemophilia. In coming years use of desmopressin should increase, thus resulting in hemophilia treatment market growth.
According to National Hemophilia Foundation, hemophilia A is almost 4 times more prevalent than hemophilia B. The number of people with hemophilia in United States is estimated to be around 20,000. Increase in number of people suffering from hemophilia A will result rising treatment demand, fueling the segment growth.
U.S. hemophilia treatment market is estimated to dominate the North America region during the projection period. Increasing prevalence of hemophilia across the country, enhanced healthcare infrastructure and recent technological advancements in hemophilia treatment will propel the industry growth. Also, presence of big pharmaceutical companies such as Sanofi, Bioverativ and Roche in U.S. will foster the growth of hemophilia market.
India hemophilia treatment market is estimated to show substantial growth over the forthcoming years. According to a recent study it was observed that around 14,000 people suffering from hemophilia are registered at Hemophilia Federation of India. Hemophilia also remains one of the most under diagnosed diseases in India. Increasing prevalence of hemophilia, high cases of under diagnosed hemophilia cases and improving healthcare infrastructure in country will result in immense market growth.
Some of the key industry players include Baxter International, Grifols SA, CSL Ltd., Octapharma AG, Novo Nordisk, Kedrion, Pfizer, Bayer AG, Biogen Idec and Hospira. The key pharmaceutical companies concentrate on new product launches and development, increasing R&D investments and product innovation in order to garner significant revenue.
Hemophilia Treatment Market by Product, 2013-2024 (USD Million)
- Recombinant coagulation factor concentrates
- Plasma derived coagulation factor concentrates
- Antifibrinolytic agents
Hemophilia Treatment Market by disease type, 2013-2024 (USD Million)
- Hemophilia A
- Hemophilia B
- Hemophilia C
The above information is provided for the following regions and countries:
- North America
- Asia Pacific
- Latin America
- Middle East and Africa
- Saudi Arabia
- South Africa
- Baxter International
- Grifols SA
- CSL Ltd.
- Octapharma AG
- Novo Nordisk
- Bayer AG
- Biogen Idec
What Information does this report contain?
Customize this Report
Our Market Research Reports Include:
- Market snapshot
- Market Segmentation
- Value Chain Analysis
- Growth Dynamics
- Potential Market Opportunities
- Regulatory Overview
- Technology Evolution
- Innovation & Sustainability
Why Global Market Insights?Comprehensive Research
- All-inclusive coverage
- In-depth and granular data (ex: information for 8 to 15 countries, with clients open to add to this list, in each report)
- Penetrative insights & latest trends
- Offers holistic understanding of the market
- Unique methodology
- Iterative in nature to eliminate errors
- Detailed methodology, scope, assumptions and data sources available for reference
- Committed to making a positive difference for our clients
- Given the nature of this industry, we are committed to ensure that our clients get maximum return on their investment in our services
- Every purchase comes with an option to obtain additional information:
- up to 10% of the original cost
- 45-minute analyst tele-call to obtain further clarity on the market.
- Global Market Insights, Inc. strictly adheres to PCI-DSS security norms.
- Only PCI-DSS compliant payment methods used for highest level of client data security
Connect with our sales team